Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native in...
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 460
- Registration Number
- NCT00000949
- Locations
- ๐บ๐ธ
Southern New Jersey AIDS Clinical Trials, Camden, New Jersey, United States
๐บ๐ธWashington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
๐บ๐ธLouisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-11-02
- Target Recruit Count
- 92
- Registration Number
- NCT00013663
- Locations
- ๐บ๐ธ
New York Hosp - Cornell Med Ctr, New York, New York, United States
Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 78
- Registration Number
- NCT00000821
- Locations
- ๐บ๐ธ
Natl Inst of Allergy & Infect Dis / Cln Ctr, Bethesda, Maryland, United States
A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 200
- Registration Number
- NCT00000870
- Locations
- ๐บ๐ธ
The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
๐บ๐ธBeth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States
๐บ๐ธCase CRS, Cleveland, Ohio, United States
Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study)
- First Posted Date
- 2001-03-26
- Last Posted Date
- 2011-08-08
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 1695
- Registration Number
- NCT00013611
- Locations
- ๐บ๐ธ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.